Similarly, amplification of the PAK (p21-activated kinase) pathway is characteristic of BRAF-wild type melanoma [38], while in BRAF-mutant melanoma it is responsible for resistance to MAPK-inhibitor treatment [39]. This evidence concerns the gene BRAF and melanoma.